tbuckley/cabot-search huggingface dataset:
Nephropathy of secondary syphilis. A clinical and pathological spectrum
Authors: M. S. Bhorade
Journal: JAMA (1971)

Two patients illustrate the clinical and pathological spectrum of renal involvement in secondary syphilis. The first patient had a transient nephrotic syndrome (acute syphilitic nephrosis), with mild proliferative changes shown on light microscopy and subepithelial electron-dense deposits on electron microscopy. The second patient had hemorrhagic nephritis, with diffuse, axial, proliferative and exudative changes shown on light microscopy and subepithelial hump-like deposits on electron microscopy. Immunofluorescent study, done in the first case, revealed subepithelial deposits of IgG and complement (β<sub>1</sub>c-globulin) along the glomerular basement membrane. This provides further evidence that the nephropathy of secondary syphilis is an immune-complex disease.
Esophageal disease
Authors: Oliver Pech
Journal: Endoscopy (2013)

During the 2013 Digestive Disease Week (DDW) (May 18 – 21, Orlando, Fla) many exciting and important endoscopy-related studies on esophageal disease were presented. Most studies were on diagnosis and endoscopic treatment of Barrett’s esophagus and related neoplasia. However, also other topics such as eosinophilic esophagitis, peroral endoscopic myotomy (POEM) in achalasia patients, Zenker’s myotomy, and endoscopic treatment of squamous cell cancer had several relevant scientific contributions. The following review discusses my personal subjective selection of 18 important endoscopy abstracts from this year’s DDW.
T cell exhaustion dynamics are linked to clinical outcomes in hepatocellular carcinoma
Authors: Zhen Zhang, Catrin Tauber, Moritz Hess, Sasikanth Manne, Annette Schmitt-Gräff, Frances Winkler, Takuya Ohtani, Tobias Flecken, Patricia Otto-Morra, Michael Schultheiss, Bettinger Dominik, Andrew Rech, David J. Pinato, Marcus Buggert, Thomas Berg, Stefan Fichtner-Feigl, Harald Binder, E. John Wherry, Maike Hofmann, Robert Thimme, Bertram Bengsch
Journal: Journal of Hepatology (2020)
Is it time to include lipoprotein analysis in cholesterol screening?
Authors: B. Merz
Journal: JAMA (1989)

DO CHOLESTEROL screening tests that do not include lipoprotein analysis provide an accurate assessment of risk of coronary heart disease? Quite often they do not, according to the results of two recently reported studies. <h3>HDL-C An Independent Risk Factor?</h3> The results of the larger factor of the two, conducted by the Framingham (Mass) Study Group (<i>Arteriosclerosis</i>1988;8:207-211), indicate that when an overall serum cholesterol reading is the only parameter used to determine risk of coronary heart disease a significant number of high-risk patients may go undetected. The reason, says Framingham's chief investigator, William Castelli, MD, is that high-density lipoprotein cholesterol (HDL-C) is emerging as an independent risk factor. From 1969 to 1971, the Framingham group determined fasting levels of HDL-C in 1007 men and 1418 women aged 50 to 79 years, all of whom were free of coronary heart disease. They followed up the group for 12 years after measurement
Magnesium Metabolism
Authors: Warren E. C. Wacker, Alfred F. Parisi
Journal: New England Journal of Medicine (1968)

OVER the decade since this subject was last reviewed in the Journal 1 much has been added to the knowledge of normal human magnesium metabolism and of its alteration in disease. This has ensued largely because of the advances made in the quantitative analysis of this element in biologic samples. A major step forward has been the successful use of flame methods to measure magnesium in body fluids and tissues. Application of the technics of emission spectroscopy led to the perfection of a multichannel flame spectrometer that gave precise and accurate determinations of the relatively small amounts of magnesium in serum, . . .
DOMESTIC CORRESPONDENCE.
Authors: Eugene L. Fridenberg
Journal: JAMA (1883)

Falls City, Neb., Sept.23, 1883. N. S. Davis, M.D. I notice that inThe Journalof August 18, 1883, Dr. Bénj. F. Bache is given the credit of first using heat as a disinfectant. If my memory serves me correctly, Dr. Henry, of Manchester, England, in 1824, used it to destroy the contagious property of smallpox, vaccine virus, typhus and scarlet fever; and in 1851, Dr. Van Busch, of Berlin, made a trial of the same agent in a large lying-in hospital, in the wards of which puerperal fever had been very destructive, and obtained most favorable results. Did Dr. Bache's experiment occur before the above dates? Very respectfully,
Drip infusion pyelography
Authors: A. D. Pratt
Journal: JAMA (1967)

In a series of 2,600 cases at the Christ Hospital, drip infusion pyelography has been demonstrated to be as safe and well-tolerated as standard-dose pyelography; and drip infusion pyelography produces much better visualization. The improvement in visualization of the collecting systems led to a 30% reduction in the number of retrograde pyelograms performed. Drip infusion pyelography has become our routine method of examining the urinary tract with contrast materials.
Error in Abstract
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
STRAMONIUM AS A THERAPEUTIC AGENT IN THE SEQUELAE OF EPIDEMIC ENCEPHALITIS
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 vs. placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: a phase 2 randomised controlled trial (FASCINATE-1)
Authors: Rohit Loomba, Mary Rinella, Stephen Harrison, Vincent Wai-Sun Wong, Vlad Ratziu, Rizwana Mohseni, Kathryn Jean Lucas, Robert G. Perry, Robert Rahmini, James F. Trotter, Julio Gutierrez, Katharine Grimmer, William McCulloch, Marie O’Farrell
Journal: Journal of Hepatology (2020)
Modern Dentistry.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TNF?-induced apoptosis of hepatocytes precedes massive hepatic necrosis during the course of acute hepatic failure First Dept. of Medicine, Osaka University Medical School, Suita and *Rohto Pharm, Co., Osaka, Japan
Journal: Hepatology (1995)

Biochanin A, an isoflavone existed in red clover and peanuts, has been reported to possess a wide spectrum of pharmacological activities, such as anti-inflammatory and antioxidant effects. However, the protective effects and mechanism of biochanin A on liver injury have not been reported. In this study, acute liver injury was induced by intraperitoneal injection of lipopolysaccharide (LPS) and d-galactosamine (D-GalN). Biochanin A was administrated 1 h prior to LPS/D-GalN challenge. Serum ALT, AST, IL-1β, and TNF-α levels, hepatic malondialdehyde (MDA), GPx, SOD, and Catalase contents, tissue histology, IL-1β, TNF-α, NLRP3, and Nrf2 expression were detected. The results showed that serum ALT, AST, IL-1β, and TNF-α levels and hepatic MDA content increased after LPS/GalN treatment. These changes were attenuated by biochanin A. Meanwhile, biochanin A dose-dependently up-regulated the expression of Nrf2 and HO-1. Biochanin A also inhibited hepatic IL-1β and TNF-α expression in a dose-dependent manner. Biochanin A did not inhibit LPS/D-GalN-induced hepatic NLRP3, ASC, and caspase-1 expression. However, the interaction of NLRP3 with ASC and caspase-1 were inhibited by biochanin A. In addition, LPS/D-GalN-induced up-regulation of thioredoxin-interacting protein (TXNIP) and interaction between TXNIP and NLRP3 were also inhibited by biochanin A. In conclusion, biochanin A protected against LPS/GalN-induced liver injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation.
Ventricular asystole after edrophonium chloride administration
Authors: R. M. Rossen
Journal: JAMA (1976)

EDROPHONIUM chloride (Tensilon) is a rapidly acting anticholinesterase drug of short duration. It has been widely used in the evaluation and treatment of supraventricular arrhythmias, such as paroxysmal atrial and paroxysmal junctional tachycardia.<sup>1-2</sup>Reported complications have included sinus bradycardia, atrioventricular (AV) block, and, rarely, ventricular asystole.<sup>3-4</sup>In our case, ventricular asystole followed the rapid intravenous infusion of 10 mg of edrophonium chloride, in a patient with acute anterior and inferior myocardial infarction. <h3>Report of a Case</h3> A 66-year-old woman was admitted to Stanford University Hospital because of left precordial and arm pain of 14 hours' duration. She had a past history of essential hypertension treated with thiazide diuretics, and on admission she was normotensive, with a pulse rate of 66 beats per minute. Bilateral basilar rales were heard over the posterior lung fields, and a protodiastolic (S<sub>3</sub>) gallop was present. Chest roentgenogram showed a normal heart size and
The Heartbreak of Drug Pricing
Authors: Frank Davidoff
Journal: Annals of Internal Medicine (2002)

Letters4 June 2002The Heartbreak of Drug PricingFrank Davidoff, MDFrank Davidoff, MDEditor Emeritus (Davidoff)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-11-200206040-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:As Dr. Ross notes, companies do, of course, have a fiduciary obligation to their stockholders, but my editorial was intended to appeal to forces in corporate life other than purely fiscal ones. In fact, many pharmaceutical companies, as well as those in other sectors of the economy, take seriously their nonfinancial obligations, including those to their customers and other parts of the community, not just because it's the “right thing” to do but because it makes good, hard business sense. A well-known example is Johnson & Johnson's credo, which begins: “We believe our first responsibility is to ...References1. Our credo. Johnson & Johnson. Available at www.jnj.com/who_is_jnj/cr_usa.html. Google Scholar2. Davidoff F. Changing the subject: ethical principles for everyone in health care [Editorial]. Ann Intern Med. 2000;133:386-9. [PMID: 10979885] LinkGoogle Scholar3. Davidoff F, Reinecke RD. The 28th Amendment [Editorial]. Ann Intern Med. 1999;130:692-4. [PMID: 10215568] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Editor Emeritus (Davidoff) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe 28th Amendment Frank Davidoff and Robert D. Reinecke Changing the Subject: Ethical Principles for Everyone in Health Care Frank Davidoff The Heartbreak of Drug Pricing Frank Davidoff The Heartbreak of Drug Pricing Johnathon S. Ross The Heartbreak of Drug Pricing Wes Lisker Metrics 4 June 2002Volume 136, Issue 11Page: 853-854KeywordsDrug pricesDrugsFood and Drug AdministrationHealth care ePublished: 4 June 2002 Issue Published: 4 June 2002 CopyrightCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis
Authors: P. L. Bailin
Journal: JAMA (1975)

The use of methotrexate in psoriasis has recently been questioned because of possible carcinogenic potential. Two hundred twenty-four patients began methotrexate therapy during 1960 to 1965 at the Cleveland Clinic and at Duke University Medical Center. The incidence of malignant neoplasms and mortality has been studied in 205 of these 224 patients. Mortality increased with hepatic disease. No increased incidence of total internal malignancy was found, nor did any one type of neoplasm appear predominant. (<i>JAMA</i>232:359-362, 1975)
Pharmaceutical Mathematics.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA
Authors: Christopher Alvarez-Breckenridge, Anita Giobbie-Hurder, Corey Gill, Mia Bertalan, Jackson Stocking, Alexander Kaplan, Naema Nayyar, Donald Lawrence, Keith Flaherty, Helen Shih, Kevin Oh, Tracy Batchelor, Daniel Cahill, Ryan Sullivan, Priscilla Brastianos
Journal: Neuro-Oncology (2018)

Immune checkpoint blockade has systemic efficacy in patients with metastatic melanoma, including those with brain metastases. However, immunotherapy-induced intracranial tumoral inflammation can lead to neurologic compromise, requiring steroids, which abrogate the systemic efficacy of this approach. We hypothesize that early surgical intervention creates an opportunity for improved survival amongst patients undergoing immune checkpoint blockade for metastatic melanoma. An IRB approved, single institution retrospective study identified 142 patients with melanoma brain metastases treated with immune checkpoint blockade. Overall survival was calculated from date of diagnosis of brain metastasis until death from any cause. Model building included a prognostic model of overall survival and the effect of sequencing of immunotherapy and surgery on overall survival. The 2-year overall survival for patients treated with CTLA-4, PD-1 or combinatorial blockade were 19%, 54%, and 57%, respectively. Patients undergoing surgery for melanoma brain metastases prior to immunotherapy had a median survival of 22.7 months (95% CI: 12.6 to 39.2) compared to 9.3 months (95% CI: 5.7 to 31.1) for patients undergoing surgery after immunotherapy (P=0.06). Amongst surgical patients, the sequence of immunotherapy, diagnosis of brain metastases, and surgery was significantly associated with the hazard of death (P=0.002). Surgery for treatment-naïve intracranial disease followed by immunotherapy is associated with increased overall survival compared to patients who underwent surgery for brain metastases that developed on immunotherapy (HR: 2.96, 95% CI: 1.4 to 6.1). These results suggest that in treatment-naïve patients, early surgical resection for local control should be considered prior to commencing immunotherapy.
Contents: (Adv. Healthcare Mater. 4/2017)
Journal: Advanced Healthcare Materials (2017)

Hemocompatibility of Superhemophobic Titania SurfacesThe hemocompatibility of superhemophobic surfaces is investigated and compared with that of hemophobic surfaces and hemophilic surfaces.This analysis indicates that only those superhemophobic surfaces with a robust Cassie-Baxter state display significantly lower platelet adhesion and activation.It is envisioned that the understanding gained through this work will lead to the fabrication of improved hemocompatible, superhemophobic medical implants.
Oral Leukoplakia
Authors: Gerald Shklar
Journal: New England Journal of Medicine (1986)

"Oral leukoplakia" is a term used to describe reasonably common, nonspecific, white plaque-like areas of oral mucosa, which develop in response to local irritation. The implications of leukoplakia as a precancerous condition and its relation to smoking were first recognized as early as 1870 by James Paget, who used clinical terms such as "ichthyosis," "smoker's patch," or "leucokeratosis." "Leukoplakia" was first used by Schwimmer in 1877 and has remained the term of choice since that time. Within the variety of cases described under this term, it was understood that some lesions were innocuous whereas others represented true precancerous lesions. In . . .
Reply
Authors: Sylvie Naveau
Journal: Hepatology (2004)

We thank Mookerjee et al. for the interest expressed about our article.1 Effectively, the more frequent infections in the infliximab group may be explained by the high total dosage of infliximab we have used in patients with a high risk of infection. Nevertheless, as highlighted in our manuscript, no relationships have been found between the dose of infliximab and the incidence or severity of infections in previous large trials on Crohn's disease2 or rheumatoid arthritis.3 Such trials involved large numbers of patients treated with 10 mg/kg per injection. We chose to treat our patients with infliximab plus corticosteroids because, in our opinion, it was unethical not to treat patients with corticosteroids, since this treatment is the only one that has been shown to improve survival in severe acute alcoholic hepatitis. Currently it is standard practice to combine infliximab with immunosuppressants and corticosteroids as a second or third line of treatment. This is the case in Crohn's disease, rheumatoid arthritis, vasculitis, and psoriasis. Thus, the combination of corticosteroids with infliximab, as in this study, is commonplace. Moreover, there is no clear association between serious infections and concomitant therapy with corticosteroids. Colombel et al. have recently reported that the rate of infectious events in patients with Crohn's disease is not correlated with the number of infusions, and that there is no association between serious infection and concomitant therapy with corticosteroids.4 Very importantly, in contrast to its impact on the incidence of infection, infliximab had no beneficial effects on liver function. In addition, there were no differences between the two groups for the plasma levels of tumor necrosis factor (TNF) receptor p55 (TNFsRp55), TNFsRp75, intercellular adhesion molecule-1, interleukin (IL) 10, IL-6, both unstimulated and lipopolysaccharide-induced IL-10, and TNF-α production by monocytes (data not shown). These findings do not provide supportive arguments to start a new trial of infliximab for severe alcoholic hepatitis. Sylvie Naveau*, * Services d'Hépato-Gastro-Entérologie, Hôpital Antoine Bédère, Assistance Publique-Hôpital de Paris, Clamart, France.
Response
Authors: J. P. Van Nevel
Journal: JNCI Journal of the National Cancer Institute (1997)

In the October 16 ''News'' section of the Journal, Richard Klein of the National Center for Health Statistics intended to cover only cancer-related objectives unique to women in his Stat Bite.However, the ''News'' section frequently covers tobacco issues.For example, we carried an article in the October 2 issue and three articles on tobacco issues in the September 4 issue.We also carried a separate article on combined therapy for lung cancer in the September 4 issue.Tobacco is a major problem and we will continue to cover it.
<i>Des Troubles du Langage chez les Aliénés.</i> (Disorders of Speech in the Insane.) Par J. SÉGLAS. Médecin Supplént de la Salpêtrière,&amp;c. Avec 17 Figures intercallées dins le texte. Paris: J. Rueff &amp; Cie., Editeurs, 106, Boulevard, St. Germain, 1892
Authors: T. H. K.
Journal: American Journal of Psychiatry (1892)
The Adrenogenital Syndrome
Authors: Alfred M. Bongiovanni, Allen W. Root
Journal: New England Journal of Medicine (1963)

A brief resume of the adrenocortical enzymes concerned with the steroidal transformations discussed herein and a partial review of the literature follow. The enzyme (or enzymes) responsible for the conversation of pregnenolone to progesterone (1 to 2 in Fig. 1) is termed 3-beta-hydroxysteroid dehydrogenase (A). This catalyzes the oxidation of the -OH group in the C-3 position, and it is probable that a second enzyme, "isomerase," converts the unsaturated compound from Δ5 to Δ4, although this alteration is known to occur in the course of ordinary chemical oxidation of this hydroxyl group. The enzyme, 3-beta-hydroxysteroid dehydrogenase, was . . .